CDT Equity partners with QIMA to evaluate tapinarof combinations
CDT Equity Inc. said it has partnered with QIMA Life Sciences to evaluate proprietary tapinarof combinations in psoriasis and vitiligo using human patient skin.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
CDT Partners With QIMA Life Sciences to Evaluate Tapinarof Combinations
CDT Equity Inc. (NASDAQ:CDT) announced a partnership with QIMA Life Sciences to explore novel tapinarof combinations for psoriasis and vitiligo.
CDT - CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo
CDT - CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo